Cargando…

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial

BACKGROUND: Eteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production. OBJECTIVE: To report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonald, Craig M., Shieh, Perry B., Abdel-Hamid, Hoda Z., Connolly, Anne M., Ciafaloni, Emma, Wagner, Kathryn R., Goemans, Nathalie, Mercuri, Eugenio, Khan, Navid, Koenig, Erica, Malhotra, Jyoti, Zhang, Wenfei, Han, Baoguang, Mendell, Jerry R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673535/ https://www.ncbi.nlm.nih.gov/pubmed/34120909 http://dx.doi.org/10.3233/JND-210643

Ejemplares similares

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
por: Mendell, Jerry R., et al.
Publicado: (2021)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial
por: Wagner, Kathryn R., et al.
Publicado: (2021)

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53
por: Brogna, Claudia, et al.
Publicado: (2019)

North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up
por: Coratti, Giorgia, et al.
Publicado: (2021)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
por: Servais, Laurent, et al.
Publicado: (2022)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
por: Beckers, Pablo, et al.
Publicado: (2021)

A Duchenne Muscular Dystrophy Gene Hot Spot Mutation in Dystrophin-Deficient Cavalier King Charles Spaniels Is Amenable to Exon 51 Skipping
por: Walmsley, Gemma L., et al.
Publicado: (2010)

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
por: Alfano, Lindsay N., et al.
Publicado: (2019)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study
por: Brogna, Claudia, et al.
Publicado: (2023)

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment
por: Mitelman, Olga, et al.
Publicado: (2022)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
por: Clemens, Paula R., et al.
Publicado: (2020)

Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History
por: Kinane, T. Bernard, et al.
Publicado: (2018)

Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia
por: Aiello, Gregory M., et al.
Publicado: (2022)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
por: Eser, Gökçe, et al.
Publicado: (2022)

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
por: Iff, Joel, et al.
Publicado: (2023)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2018)

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
por: Echigoya, Yusuke, et al.
Publicado: (2018)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
por: Gapinske, Michael, et al.
Publicado: (2023)

A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping
por: Echigoya, Yusuke, et al.
Publicado: (2021)

Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish
por: Berger, Joachim, et al.
Publicado: (2011)

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2017)

Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies
por: Hoffman, Eric P.
Publicado: (2020)

ExonSkipDB: functional annotation of exon skipping event in human
por: Kim, Pora, et al.
Publicado: (2020)

Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
por: Jirka, Silvana M G, et al.
Publicado: (2015)

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype
por: Servais, Laurent, et al.
Publicado: (2015)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
por: Lilien, Charlotte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aa9uv8crl1qh1bd4noq7sj3kj7